Northern Trust Corp Medicinova Inc Transaction History

Northern Trust Corp

  • $658 Billion
  • Q1 2025

A detailed history of Northern Trust Corp transactions in Medicinova Inc stock. As of the latest transaction made, Northern Trust Corp holds 140,751 shares of MNOV stock, worth $188,606. This represents 0.0% of its overall portfolio holdings.

Number of Shares
140,751
Previous 141,012 0.19%
Holding current value
$188,606
Previous $296,000 30.74%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 13, 2025
SELL
$1.46 - $2.16 $381 - $563
-261 Reduced 0.19%
140,751 $205,000
Q3 2024

Nov 13, 2024
SELL
$1.13 - $2.1 $5,517 - $10,254
-4,883 Reduced 3.35%
141,012 $296,000
Q2 2024

Aug 14, 2024
SELL
$1.28 - $1.57 $9,701 - $11,899
-7,579 Reduced 4.94%
145,895 $210,000
Q1 2024

May 14, 2024
SELL
$1.28 - $1.65 $104 - $135
-82 Reduced 0.05%
153,474 $222,000
Q4 2023

Feb 13, 2024
SELL
$1.38 - $2.06 $197 - $294
-143 Reduced 0.09%
153,556 $230,000
Q3 2023

Nov 13, 2023
SELL
$2.01 - $2.6 $980 - $1,268
-488 Reduced 0.32%
153,699 $321,000
Q2 2023

Aug 11, 2023
SELL
$2.09 - $2.43 $3,249 - $3,778
-1,555 Reduced 1.0%
154,187 $354,000
Q1 2023

May 15, 2023
SELL
$1.95 - $2.54 $12,645 - $16,471
-6,485 Reduced 4.0%
155,742 $336,000
Q4 2022

Feb 13, 2023
SELL
$1.97 - $2.66 $1,174 - $1,585
-596 Reduced 0.37%
162,227 $332,000
Q3 2022

Nov 14, 2022
BUY
$2.1 - $2.6 $6,879 - $8,517
3,276 Added 2.05%
162,823 $353,000
Q2 2022

Aug 12, 2022
SELL
$2.31 - $3.14 $3,298 - $4,483
-1,428 Reduced 0.89%
159,547 $403,000
Q1 2022

May 13, 2022
SELL
$2.19 - $2.81 $3,992 - $5,122
-1,823 Reduced 1.12%
160,975 $430,000
Q4 2021

Feb 08, 2022
BUY
$2.61 - $4.42 $30,281 - $51,280
11,602 Added 7.67%
162,798 $437,000
Q3 2021

Nov 15, 2021
BUY
$3.4 - $4.24 $1,696 - $2,115
499 Added 0.33%
151,196 $573,000
Q2 2021

Aug 13, 2021
SELL
$3.76 - $5.14 $1.38 Million - $1.88 Million
-366,572 Reduced 70.87%
150,697 $641,000
Q1 2021

May 12, 2021
SELL
$4.81 - $8.74 $389,133 - $707,074
-80,901 Reduced 13.52%
517,269 $2.61 Million
Q4 2020

Feb 11, 2021
SELL
$5.03 - $6.31 $136,665 - $171,442
-27,170 Reduced 4.34%
598,170 $3.15 Million
Q3 2020

Nov 16, 2020
SELL
$4.67 - $11.0 $94,941 - $223,630
-20,330 Reduced 3.15%
625,340 $3.28 Million
Q2 2020

Aug 14, 2020
BUY
$3.06 - $7.06 $250,592 - $578,164
81,893 Added 14.53%
645,670 $3.5 Million
Q1 2020

May 14, 2020
BUY
$2.9 - $6.97 $67,952 - $163,321
23,432 Added 4.34%
563,777 $2.1 Million
Q4 2019

Feb 14, 2020
SELL
$6.48 - $8.76 $100,044 - $135,245
-15,439 Reduced 2.78%
540,345 $3.64 Million
Q3 2019

Nov 13, 2019
BUY
$7.7 - $10.42 $230,122 - $311,412
29,886 Added 5.68%
555,784 $4.42 Million
Q2 2019

Aug 13, 2019
BUY
$8.29 - $13.22 $163,727 - $261,095
19,750 Added 3.9%
525,898 $5.07 Million
Q1 2019

May 13, 2019
BUY
$6.82 - $10.27 $55,064 - $82,919
8,074 Added 1.62%
506,148 $4.19 Million
Q4 2018

Feb 12, 2019
SELL
$7.65 - $12.83 $4,811 - $8,070
-629 Reduced 0.13%
498,074 $4.07 Million
Q3 2018

Nov 14, 2018
BUY
$7.06 - $12.49 $307,625 - $544,226
43,573 Added 9.57%
498,703 $6.23 Million
Q2 2018

Sep 18, 2018
SELL
$7.96 - $13.23 $20,703 - $34,411
-2,601 Reduced 0.57%
455,130 $3.62 Million
Q2 2018

Aug 14, 2018
BUY
$7.96 - $13.23 $327,569 - $544,440
41,152 Added 9.88%
457,731 $3.64 Million
Q1 2018

May 09, 2018
BUY
$6.6 - $13.91 $298,683 - $629,497
45,255 Added 12.19%
416,579 $4.26 Million
Q4 2017

Feb 14, 2018
BUY
$5.89 - $7.21 $6,496 - $7,952
1,103 Added 0.3%
371,324 $2.4 Million
Q3 2017

Nov 13, 2017
BUY
$4.43 - $6.58 $1.64 Million - $2.44 Million
370,221
370,221 $2.36 Million

Others Institutions Holding MNOV

# of Institutions
28
Shares Held
5.1M
Call Options Held
28.5K
Put Options Held
0
View Full List

About MEDICINOVA INC

MNOV Quotes by TradingView
  • Ticker MNOV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,046,200
  • Market Cap $65.7M
  • Description
  • MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...
More about MNOV
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email